Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398281 · ClinicalTrials.gov registry record · Phase 3
Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer
A Phase 3 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
NCT00398281 is a Phase 3 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 450 participants.
The verdict
NCT00398281, a Phase 3 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures, such as ultrasound-guided biopsy, may help find prostate cancer. Dutasteride may improve the ability of ultrasound-guided biopsy to find prostate cancer. It is not yet known whether dutasteride followed by ultrasound-guided biopsy is more effective than a placebo followed by ultrasound-guided biopsy in finding prostate cancer. PURPOSE: This randomized phase III trial is studying dutasteride and ultrasound-guided biopsy to see how well they find prostate cancer compared with a placebo and ultrasound-guided biopsy.
Interventions
- OTHER placebo
- DRUG dutasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2006-11 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00398281
The ClinicalTrials.gov registry entry for NCT00398281 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00398281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00398281 about?
NCT00398281 is a clinical study titled "Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer". RATIONALE: Diagnostic procedures, such as ultrasound-guided biopsy, may help find prostate cancer. Dutasteride may improve the ability of ultrasound-guided biopsy to find prostate cancer. It is not yet known whether dutasteride followed by ultrasound-guided biopsy is more effective than a placebo fo...
What is the current status of trial NCT00398281?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2006-11. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00398281?
The interventions under investigation include: placebo (OTHER), dutasteride (DRUG).
Who is sponsoring clinical trial NCT00398281?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.